Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

Journal of Experimental Medicine

Volumn 200, Issue 6, 2004, Pages 771-782

  Turk, Mary Jo ^a   Guevara Patiño, José A ^a   Rizzuto, Gabrielle A ^a   Engelhorn, Manuel E ^a   Houghton, Alan N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer immunity; Cyclophosphamide; GITR; Immune suppression; Melanocyte differentiation antigen

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DTA 1; RAG1 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; HELPER CELL; IMMUNOGENICITY; LYMPHOCYTE DEPLETION; MALE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, DIFFERENTIATION; CYCLOPHOSPHAMIDE; GENES, RAG-1; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-10; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 4644342928     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20041130     Document Type: Article

References (47)

1. Ehrlich, P. 1906. Collected Studies on Immunity. J. Wiley & Sons, London, England.
2. Bashford, E., J. Murray, and M. Haaland. 1908. Resistance and susceptibility to inoculated cancer. In Third Scientific Report on the Investigations of the Imperial Cancer Research Fund. E. Bashford, editor. Taylor & Francis, London, England. 359-397.
3. North, R.J., and I. Bursuker. 1984. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J. Exp. Med. 159:1295-1311.
4. Berendt, M.J., R.J. North, and D.P. Kirstein. 1978. The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant antitumor immunity. J. Exp. Med. 148:1560-1569.
5. Berendt, M.J., and R.J. North. 1980. T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151:69-80.
6. Bursuker, I., and R.J. North. 1985. Suppression of generation of concomitant antitumor immunity by passively transferred suppressor T cells from tumor-bearing donors. Cancer Immunol. Immunother. 19:215-218.
7. Bursuker, I., and R.J. North. 1986. Immunological consequences of tumor excision: from active immunity to immunological memory. Int. J. Cancer. 37:275-281.
8. DiGiacomo, A., and R.J. North. 1986. T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J. Exp. Med. 164:1179-1192. (published erratum appears in J. Exp. Med. 1986. 164:2131)
9. DiGiacomo, A., and R.J. North. 1986. T cell suppressors of antitumor immunity. The production of Ly-1-,2+ suppressors of delayed sensitivity precedes the production of suppressors of protective immunity. J. Exp. Med. 164:1179-1192. (published erratum appears in J. Exp. Med. 1986. 164:2131)
10. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
11. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057-1061.
12. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151-1164.
13. Shimizu, J., S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi. 2002. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3:135-142.
14. Turk, M.J., J.D. Wolchok, J.A. Guevara-Patino, S.M. Goldberg, and A.N. Houghton. 2002. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188:122-135.
15. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-832.
16. Shimizu, J., S. Yamazaki, and S. Sakaguchi. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-5218.
17. Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J.E. de Vries, and M.G. Roncarolo. 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389:737-742.
18. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D.D. Donaldson, D.P. Carbone, W.E. Paul, and J.A. Berzofsky. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-520.
19. Moodycliffe, A.M., D. Nghiem, G. Clydesdale, and S.E. Ullrich. 2000. Immune suppression and skin cancer development: regulation by NKT cells. Nat. Immunol. 1:521-525.
20. Sonoda, K.H., and J. Stein-Streilein. 2002. Ocular immune privilege and CD1d-reactive natural killer T cells. Cornea. 21:S33-S38.
21. Gorelik, E. 1983. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv. Cancer Res. 39:71-120.
22. Sonoda, K.H., M. Exley, S. Snapper, S.P. Balk, and J. Stein-Streilein. 1999. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 190:1215-1226.
23. Hara, I., H. Nguyen, Y. Takechi, B. Gansbacher, P.B. Chapman, and A.N. Houghton. 1995. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int. J. Cancer. 61:253-260.
24. Awwad, M., and R.J. North. 1988. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology. 65:87-92.
25. Bloom, M.B., D. Perry-Lalley, P.F. Robbins, Y. Li, M. el-Gamil, S.A. Rosenberg, and J.C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453-459.
26. Overwijk, W.W., A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
27. Scheibenbogen, C., K.H. Lee, S. Stevanovic, M. Witzens, M. Willhauck, V. Waldmann, H. Naeher, H.G. Rammensee, and U. Keilholz. 1997. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int. J. Cancer. 71:932-936.
28. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R.C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:3539-3543.
29. Kojima, T., K. Yamazaki, Y. Tamura, S. Ogura, K. Tani, J. Konishi, N. Shinagawa, I. Kinoshita, N. Hizawa, E. Yamaguchi, H. Dosaka-Akita, and M. Nishimura. 2003. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice. Hum. Gene Ther. 14:715-728.
30. Awwad, M., and R.J. North. 1989. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res. 49:1649-1654.
31. North, R.J. 1982. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 155:1063-1074.
32. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, and F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34:336-344.
33. Gershon, R.K., R.L. Carter, and K. Kondo. 1967. On concomitant immunity in tumour-bearing hamsters. Nature. 213:674-676.
34. Belehradek, J., Jr., G. Barski, and M. Thonier. 1972. Evolution of cell-mediated antitumor immunity in mice bearing a syngeneic chemically induced tumor. Influence of tumor growth, surgical removal and treatment with irradiated tumor cells. Int. J. Cancer. 9:461-469.
35. Chandradasa, K.D. 1973. The development and specific suppression of concomitant immunity in two syngeneic tumour-host systems. Int. J. Cancer. 11:648-662.
36. Deckers, P.J., B.W. Edgerton, B.S. Thomas, and Y.H. Pilch. 1971. The adoptive transfer of concomitant immunity to murine tumor isografts with spleen cells from tumor-bearing animals. Cancer Res. 31:734-742.
37. Howell, S.B., J.H. Dean, and L.W. Law. 1975. Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Int. J. Cancer. 15:152-169.
38. Zarling, J.M., and S.S. Tevethia. 1973. Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. II. Evidence for macrophage participation at the effector level of tumor cell rejection. J. Natl. Cancer Inst. 50:149-157.
39. Gorelik, E., S. Segal, and M. Feldman. 1981. On the mechanism of tumor "concomitant immunity". Int. J. Cancer. 27:847-856.
40. Bowne, W.B., R. Srinivasan, J.D. Wolchok, W.G. Hawkins, N.E. Blachere, R. Dyall, J.J. Lewis, and A.N. Houghton. 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190:1717-1722.
41. Gold, J.S., C.R. Ferrone, J.A. Guevara-Patino, W.G. Hawkins, R. Dyall, M.E. Engelhorn, J.D. Wolchok, J.J. Lewis, and A.N. Houghton. 2003. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J. Immunol. 170:5188-5194.
42. Gallimore, A., and S. Sakaguchi. 2002. Regulation of tumour immunity by CD25+ T cells. Immunology. 107:5-9.
43. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128-3133.
44. + T cells in graft-versus-host disease. J. Exp. Med. 200:149-157.
45. Wang, H.I., D.A. Lee, G. Peng, Z. Guo, Y. Li, Y. Kiniwa, E.M. Shevach, and R.F. Wang. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 20:107-118.
46. Cozzo, C., J. Larkin III, and A.J. Caton. 2003. Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J. Immunol. 171:5678-5682.
47. Belkaid, Y., C.A. Piccirillo, S. Mendez, E.M. Shevach, and D.L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 420:502-507.